- Home
- RARE
RARE
Ultragenyx Pharmaceutical Inc.
as 07-26-2024 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Ultragenyx Pharmaceutical Inc. RARE prepares to release earnings report on 01 Aug 2024.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | N/A | IPO Year: | 2014 |
| Target Price: | $86.60 | AVG Volume (30 days): | 803.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.52 - $54.56 | Next Earning Date: | 08-01-2024 |
| Revenue: | $442,586,000 | Revenue Growth: | 15.29% |
| Revenue Growth (this year): | 20.62% | Revenue Growth (next year): | 20.94% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | RARE | Director | Jul 2 '24 | Sell | $40.98 | 584 | $23,932.32 | 12,009 | SEC Form 4 |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Jun 12 '24 | Sell | $45.00 | 9,806 | $441,270.00 | 57,981 | SEC Form 4 |
| Sanders Corazon (Corsee) D. | RARE | Director | Jun 10 '24 | Sell | $41.10 | 1,737 | $71,390.70 | 7,248 | SEC Form 4 |
| Crombez Eric | RARE | EVP and Chief Medical Officer | May 2 '24 | Sell | $43.66 | 354 | $15,455.64 | 48,431 | SEC Form 4 |
| Crombez Eric | RARE | EVP and Chief Medical Officer | Apr 18 '24 | Sell | $44.10 | 142 | $6,262.20 | 48,785 | SEC Form 4 |
| Kassberg Thomas Richard | RARE | CBO & EVP | Mar 11 '24 | Sell | $49.93 | 11,509 | $574,644.37 | 252,823 | SEC Form 4 |
| Fust Matthew K | RARE | Director | Mar 7 '24 | Sell | $50.88 | 7,500 | $381,600.00 | 14,860 | SEC Form 4 |
| Fust Matthew K | RARE | Director | Mar 7 '24 | Sell | $50.85 | 2,145 | $109,073.25 | 22,360 | SEC Form 4 |
| Fust Matthew K | RARE | Director | Mar 7 '24 | Sell | $50.89 | 2,550 | $129,769.50 | 24,505 | SEC Form 4 |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Mar 1 '24 | Sell | $53.76 | 3,756 | $201,922.56 | 67,340 | SEC Form 4 |
| Pinion John Richard | RARE | See Remarks | Mar 1 '24 | Sell | $53.76 | 4,173 | $224,340.48 | 89,268 | SEC Form 4 |
| Crombez Eric | RARE | EVP and Chief Medical Officer | Mar 1 '24 | Sell | $53.76 | 1,238 | $66,554.88 | 48,927 | SEC Form 4 |
| Kassberg Thomas Richard | RARE | CBO & EVP | Mar 1 '24 | Sell | $53.76 | 1,011 | $54,351.36 | 264,332 | SEC Form 4 |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Mar 1 '24 | Sell | $53.76 | 341 | $18,332.16 | 41,380 | SEC Form 4 |
| Harris Erik | RARE | EVP & Chief Commercial Officer | Mar 1 '24 | Sell | $53.76 | 4,768 | $256,327.68 | 67,163 | SEC Form 4 |
| KAKKIS EMIL D | RARE | President & CEO | Feb 7 '24 | Sell | $45.00 | 30,000 | $1,350,000.00 | 539,770 | SEC Form 4 |
| KAKKIS EMIL D | RARE | President & CEO | Dec 29 '23 | Sell | $47.87 | 30,000 | $1,436,100.00 | 569,770 | SEC Form 4 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
2 days ago
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Investor's Business Daily
4 days ago
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
GlobeNewswire
7 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zacks
8 days ago
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
MT Newswires
9 days ago
Ultragenyx Reports 'Successful' End-of-Phase 2 FDA Meeting For Angelman Syndrome Program
GlobeNewswire
9 days ago
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
GlobeNewswire
a month ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.